Cancer is an aggressive disease, and an even greater treatment is needed to overcome the complexity of disease. The treatment is known as Immunotherapy (Revival) and it potentially offer patients a hope to eradicate it permanently. At Revine Clinic, the treatment has changed the lives of many people for the better. Let’s explore this article.
Cancer treatment refers to the medical strategy to diagnose, manage, and cure cancer. When it comes to treatment options, giving the choices are as diverse as the types of cancer. Each treatment serves the same purpose, but the execution method vary like their efficiency too.
Breast cancer is a type of cancer that originates in the cells of the breast tissue. It is the most common cancer diagnosed in women worldwide, and it can also affect men although it is rare. For localized (early-stage) breast cancer, the survival rate is relatively high, around 80-90% or more. However, the rate decreases as the cancer advances, and it goes down to 23.3% at Stage 4
Colon cancer, also known as colorectal cancer, is a type of cancer that originates in the colon or rectum, which are parts of the digestive system. It typically start with the growth of abnormal cells named polyps. Localized colon cancer has a survival rate of around 80%, while the rate decreases for more advanced stages. The survival rate is around 18.8% at Stage 4.
Lung cancer is a type of cancer that begins in the cells of the lungs. It is one of the deadliest forms of cancer worldwide and affects smokers and non-smokers alike. Lung cancer survival rates are generally lower, especially for advanced stages. The survival rate for lung cancer starts from around 38% and it declines to 6.3% at Stage 4.
Lymphoma is a type of cancer that originates in the lymphatic system, which is a part of the body’s immune system. The survival rates start at 60-62% but it declines by half to around 35.5% at Stage 4.
Nasopharyngeal cancer is a type of cancer that originates in the nasopharynx, which is the upper part of the throat located behind the nose. The survival rate for nasopharyngeal cancer in Malaysia ranges from around 60-70% for localized cases, but it lowers to 26.9% at Stage 4.
The advance of cancer research in the past two decades gives way to immunotherapy. Cancer immunotherapy activates the immune system to prevent, control, and eliminate tumour cells. Despite the best treatment, the cancer cells can evolve and evade the immune system for continued growth. They may develop these adaptations to avoid eradication:
Immunology aims to strengthen the immune system to identify and destroy the cancer cells with pinpoint accuracy. The treatment overall enhances the functionality of the immune system to ease the identification of cancer cells as targets.
Immunotherapy can be personalized to deliver even greater potency on the affected areas. The treatment would uses Peripheral blood mononuclear cells (PBMCs) to as the key instigator. The idea is to harness the power of T cells to recognize and attack cancer cells more effectively. The PBMCs will be expanded for the CIK cells which are later reinfused into the patient. It would enhance the immune system to take on the cancer cells more aggressively.
The flow of the treatment can be divided into 5 phases.
Approximately 150-200ml of blood will be collected from the patient. Once completed, the immune cells extracted from the blood will enter a culture period. In the culture period, the cells will enter activation and expansion phase. The purpose is to enhance the efficiency of the cells and increase the amount of usable cells. The expansion stops when the target of 10 billion cells per transfusion is reached. The treatment length spans up to 6 weeks with one infusion per week.
In a 5-year study of CIK and control group for breast cancer, it is found that the CIK group has a higher survival rate between 80-90%. In contrast, the control group only scored around 73%. In addition, the unlikelihood of recurrence for CIK group peaked at 77% whereas the control group only hit 68%.
Moreover, when the immunotherapy is combined with chemotherapy, the CIK group has a survival rate of 78% whereas the control group only reach 42% in the third year of post-cancer free life. As a whole, the case study shows that the CIK immunotherapy kill cancer better for increased survival rate and it complements existing treatments as well.
Cancer is not the end. Even when the conventional treatments may struggle to show results, the Revival therapy offers a good chance to turn things around. The immunotherapy has been widely studied and the results are clinically proven to help patients overcome the challenges. Book a consultation today at Revine Clinic to evaluate if immunotherapy is right for you.
Immunotherapy and chemotherapy are distinct cancer treatments with different mechanisms of action. However, immunotherapy do not kill healthy cells and there are no noticeable side effects which makes it more tolerable.
Immunotherapy can be used in various stages of cancer, including advanced stages, where it has shown effectiveness in boosting the immune system to target and attack cancer cells.
Yes, clinical studies have shown that cancer can be cured with the treatment alone or in conjunction with other conventional treatments.
In general, the chances are high. However, the success of immunotherapy for cancer varies widely depending on factors such as the type of cancer, the patient’s individual characteristics, and the specific immunotherapy approach being used.